Answers are grounded in this paper and cite their sources.
Heparin-binding EGF-like growth factor (HB-EGF) exists as a membrane-anchored form (proHBEGF) and as its soluble cleaved product (sHB-EGF). The conversion (ectodomain shedding) of proHB-EGF to sHB-EGF is tightly regulated by specific metalloproteinases. Ectodomain shedding plays a central role in GPCR-mediated EGFR transactivation. Antagonizing metalloproteinases can inhibit EGFR transactivation and might be of therapeutic value, for example in cardiac hypertrophy, skin remodeling and tumor growth.
No takes yet. Share an insight, caveat, or question.
Shigeki Higashiyama (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: